> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Expanded Farxiga Indication
- URL: https://www.fdaweb.com/fda-oks-expanded-farxiga-indication/
- Published: 2023-05-09T12:00:00.000Z
- Updated: 2026-09-14T18:30:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154405

FDA has approved an expanded indication for AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure. A company [statement](https://www.astrazeneca.com/media-centre/press-releases/2023/farxiga-extended-in-the-us-for-heart-failure.html?ref=fdaweb.com) says the approval was based on positive results from the Phase 3 DELIVER trial. Farxiga was previously approved for adults with heart failure with reduced ejection fraction. The company says the latest approval means patients with heart failure can benefit from Farxiga regardless of left ventricular ejection fraction status.